Sie sind bereits registriert?
Loggen Sie sich mit Ihrem Universimed-Benutzerkonto ein:
Sie sind noch nicht registriert?
Registrieren Sie sich jetzt kostenlos auf universimed.com und erhalten Sie Zugang zu allen Artikeln, bewerten Sie Inhalte und speichern Sie interessante Beiträge in Ihrem persönlichen Bereich
zum späteren Lesen. Ihre Registrierung ist für alle Unversimed-Portale gültig. (inkl. allgemeineplus.at & med-Diplom.at)
Is Relapsed/Refractory Myeloma Curable?
CAR-T cell therapeutics represent a major advance for patients with relapsed/refractory and high-risk myeloma, but longer-term outcomes have been uncertain. Now, at a median follow-up of 61 months, investigators report efficacy and safety in 97 heavily pretreated patients who received a single infusion of ciltacabtagene autoleucel (cilta-cel) in the CARTITUDE-1 trial.
Key findings:
- One third of patients remain progression free.
- Durable responses occurred in patients with aberrant TP53 and high-risk cytogenetics.
- Twelve patients who achieved negative PET/CT also had undetectable minimal residual disease (MRD) after cilta-cel; all 12 remained negative on subsequent serial monitoring.
- No new safety concerns were identified.
Comment
The durable remissions (including MRD negativity in the subset of patients who were tested) seen here at 5 years raise the likelihood that these patients are cured. Outcomes were better in those with lower tumor burden at initiation of CAR-T therapy. Early results in patients with relapsed myeloma point toward better progression-free survival with cilta-cel than with standard combination therapy (CARTITUDE-4 trial). Our myeloma team recommends CAR-T for eligible patients as second- or third-line therapy.
Citation(s)
Author:
Jagannath S et al.
Title:
Long-term (≥5-Year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed/refractory multiple myeloma.
Source:
J Clin Oncol
2025
Jun
3; [e-pub].
(Abstract/FREE Full Text)
Empfohlen von
Michael E. Williams, MD, ScM